Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
← catalyst calendarSponsored by Neumora Therapeutics, Inc. (industry) · NMRA — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
430actual
Sites
74
Countries
Brazil, Canada, Chile +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-20 | actual | When the study began enrolling |
| Primary completion | 2026-05-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-17 | actual | The whole study's end, after follow-up |
| First posted | 2023-09-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Major Depressive Disorder
Interventions
- Drug: NMRA-335140 — also filed as BTRX 335140, CYM-53093, Navacaprant
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score
measured Baseline and up to Week 6
Permalink · NMRA's whole pipeline · Catalyst calendar · Every registered study · What changed